Comparison of non-bismuth concomitant and standard triple therapies as a first-line treatment option for Helicobacter pylori in Japan

Comparison of non-bismuth concomitant and standard triple therapies as a first-line treatment option for Helicobacter pylori in Japan - Concomitant therapies for Helicobacter pylori first line eradication

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018164

Enrollment

220

Registered

2015-07-03

Start date

2015-05-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

PPI+AMPC +CAM+MNZ PPI+AMPC+CAM

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with H.pylori infection who want to take eradication therapy. Patients who give a written informed consent.

Exclusion criteria

Exclusion criteria: Patients were excluded from the study if they were younger than 20 years or older than 80 years, were allergic to the drugs used in this therapy. Patients who are disqualified for the study by physicians.

Design outcomes

Primary

Measure	Time frame
Comparison of the eradication rate of the two regimens, PPI+AMPC +CAM+MNZ versus PPI+AMPC+CAM for first line	—

Secondary

Measure	Time frame
Comparison of the safety of the two regimens, PPI+AMPC +CAM+MNZ versus PPI+AMPC+CAM for first line	—

Countries

Japan

Contacts

Public ContactTakayoshi Suzuki

Tokai University School of Medicine Division of Gastroenterology & Hepatology

takayosh@is.icc.u-tokai.ac.jp0463-93-1121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026